The Renal Research Laboratory was established in 1976 at Prince Henry’s Hospital. It relocated to its current site in 1991. It has international standing as one of the premier renal research laboratories in the world.
The Laboratory research areas include acute graft dysfunction in transplantation, macrophages in renal injury and repair, novel therapies for renal fibrosis, progression of human kidney disease, signaling mechanisms in renal injury and targeting renal inflammation in diabetic nephropathy.
Staff numbers total twelve, comprising a laboratory manager, three senior research fellows, four research assistants and four PhD students. Nephrology also offers PhD research projects for students enrolled via Monash University and on average, the department has approximately three to four students at any given time. The laboratory also welcomes visiting overseas Fellows to the department, and over the past years has hosted numerous Fellows from China, Japan and Nepal.
Current research projects total 17, the majority sourced from the National Health and Medical Research Council. Additional minor grants are obtained from Monash University, Kidney Health Australia and pharmaceutical companies seeking specific laboratory work on their products. Current projects total seven. An average of 50 research publications are released annually.
Latest awards bestowed on staff:
- Winner Amgen Science Award at the Australian and New Zealand Society of Nephrology awards 2012
- Winner Australian and New Zealand Society of Nephrology Basic Science award 2013
- Winner Young Investigator at the Australian and New Zealand Society of Nephrology awards 2013, 2012, 2009
- Winner of the T.J. Neale Award for outstanding contribution to nephrological science the Australian and New Zealand Society of Nephrology awards 2011 and 2012
- Winner Monash Health Research Team Award 2011
- Winner Basic Science Award in a developed country 2013
Latest research progress:
Monash Health and Monash University researchers have been able to halt the progression of diabetic kidney disease, and even reverse some of its damage. This has led to the development of a new drug, and clinical trials will commence soon in the U.S.A. Although results may not be known for two years, the drug should block a chemical reaction that causes inflammation and scarring of kidneys and other organ damage caused by the disease. It will slow progression of the disease.